Table 2. Best Confirmed IRC-Assessed Overall Response in Patients With Advanced Squamous Non–Small-Cell Lung Cancer Treated With Tislelizumab Plus Doublet Chemotherapy or Chemotherapy Alone.
| Characteristic | No. (%) | ||
|---|---|---|---|
| Arm A: tislelizumab + PC (n = 120) | Arm B: tislelizumab + nab-PC (n = 119) | Arm C: PC (n = 121) | |
| BOR | |||
| CR | 5 (4) | 3 (3) | 1 (<1) |
| PR | 82 (68) | 86 (72) | 59 (49) |
| SD | 18 (15) | 19 (16) | 36 (30) |
| Non-CR/non-PD | 0 | 0 | 1 (<1) |
| PD | 12 (10) | 5 (4) | 11 (9) |
| NE/missing | 3 (3) | 6 (5) | 13 (11) |
| ORR, % (95% CI) | 73 (63.6-80.3) | 75 (66.0-82.3) | 50 (40.4-58.8) |
| Odds ratio (95% CI) | 2.9 (1.65-4.95) | 3.1 (1.78-5.41) | NA |
| DCR, % (95% CI) | 88 (80.2-92.8) | 91 (84.1-95.3) | 80 (71.9-86.9) |
| CBR, % (95% CI)a | 81 (72.6-87.4) | 80 (71.5-86.6) | 56 (46.9-65.2) |
Abbreviations: BOR, best overall response; CBR, clinical benefit rate; CR, complete response; DCR, disease control rate; IRC, independent review committee; NA, not applicable; nab, nanoparticle albumin-bound; NE, not evaluable; ORR, objective response rate; PC, paclitaxel and carboplatin; PD, progressive disease; PR, partial response; SD, stable disease.
a
Includes patients with BOR in CR or PR or 24 weeks or greater SD.